We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Philips Collaborates with Janssen on Handheld Test for Neuropsychiatric Disorders

By LabMedica International staff writers
Posted on 05 Apr 2015
Print article
Royal Philips (Amsterdam, Netherlands) has entered into a multiyear development agreement with Janssen Pharmaceutica NV (Beerse, Belgium) to develop a novel point-of-care (POC) blood test to improve the care of patients with neuropsychiatric disorders.

The collaboration unites Philips’ expertise in POC diagnostics and monitoring applications for hospital and home with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for development and manufacturing of the handheld test, which will be based on Philips’ “Minicare” system currently under development. Janssen will be responsible for the clinical validation studies, as well as commercialization of the final product. Minicare is part of Philips’ Handheld Diagnostics business (Eindhoven, Netherlands), which will be expanding its production capacity in light of the new partnership.

The blood test will be based on Minicare I-20 for immunoassays, which consists of a handheld analyzer, dedicated software, and a single-use, disposable cartridge containing the application-specific test. Based on Philips’ proprietary biosensor technology, Minicare I -20 is being developed to detect multiple target molecules at low concentrations within a single blood sample and to provide the results on the analyzer display within minutes.

“Our technology can play an important role in the management of chronic diseases,” said Frans van Houten, CEO, Royal Philips, “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.”

“Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software can be tailored to a wide range of other pharmaceuticals,” added Mr. Van Houten.

Related Links:

Royal Philips
Janssen Pharmaceutica


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.